Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
22 nov. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
11 nov. 2021 16h01 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2021 Financial Results on November 11, 2021
04 nov. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics to Attend the Sachs 21st Annual Biotech in Europe Forum (BEF)
29 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock
28 sept. 2021 16h05 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock
24 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
23 sept. 2021 16h01 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
22 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients Responses were seen in patients with...
Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit
20 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
09 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...